# EDGAR Filing Document

**Accession Number:** 0001559109
**File Stem:** 0000940400-25-003040
**Filing Date:** 2025-9
**Character Count:** 28615
**Document Hash:** 0c6d15896cdd9267c65ae22c735a92a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000940400-25-003040.hdr.sgml**: 20250929

**ACCESSION NUMBER**: 0000940400-25-003040

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250731

**FILED AS OF DATE**: 20250929

**DATE AS OF CHANGE**: 20250929

**PERIOD START**: 20251031

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ETFis Series Trust I
- **CENTRAL INDEX KEY:** 0001559109

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-22819
- **FILM NUMBER:** 251354590

**BUSINESS ADDRESS:**
- **STREET 1:** 1301 AVENUE OF THE AMERICAS
- **STREET 2:** 16TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 2125934383

**MAIL ADDRESS:**
- **STREET 1:** 1301 AVENUE OF THE AMERICAS
- **STREET 2:** 16TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETF Actively Managed Trust
- **DATE OF NAME CHANGE:** 20120926

## Series and Classes Contracts Data

### Virtus LifeSci Biotech Products ETF (Series ID: S000047354)

| Class ID   | Class Name                          | Ticker Symbol   |
|:---|:---|:---|
| C000148682 | Virtus LifeSci Biotech Products ETF | BBP             |

## Nport-Ex

Schedule of Investments - Virtus LifeSci Biotech Products ETF

July 31, 2025 (unaudited)

---

| | | |
|:---|:---|:---|
| **Security Description** | **Shares** | **Value** |
| **COMMON STOCKS - 98.9%** |  |  |
| **Health Care - 98.9%** |  |  |
| ACADIA Pharmaceuticals, Inc.\* | 20441 | $487109 |
| ADMA Biologics, Inc.\* | 20574 | 384734 |
| Agios Pharmaceuticals, Inc.\* | 12881 | 479431 |
| Alnylam Pharmaceuticals, Inc.\* | 1459 | 572278 |
| Amgen, Inc. | 1495 | 441175 |
| Amicus Therapeutics, Inc.\* | 72025 | 431430 |
| Apellis Pharmaceuticals, Inc.\* | 23073 | 515451 |
| Ardelyx, Inc.\* | 119461 | 506515 |
| Ascendis Pharma A/S (Denmark)\*<sup>(1)</sup> | 2600 | 451100 |
| Aurinia Pharmaceuticals, Inc. (Canada)\* | 53997 | 499202 |
| Axsome Therapeutics, Inc.\* | 4183 | 424073 |
| BeOne Medicines Ltd. (China)\*<sup>(1)</sup> | 1607 | 483916 |
| BioCryst Pharmaceuticals, Inc.\* | 42730 | 347822 |
| Biogen, Inc.\* | 3359 | 429952 |
| BioMarin Pharmaceutical, Inc.\* | 7758 | 448800 |
| BioNTech SE (Germany)\*<sup>(1)</sup> | 4236 | 455370 |
| Bridgebio Pharma, Inc.\* | 11208 | 529802 |
| CRISPR Therapeutics AG (Switzerland)\* | 10765 | 605639 |
| Day One Biopharmaceuticals, Inc.\* | 66427 | 445725 |
| Dynavax Technologies Corp.\* | 42730 | 469175 |
| Exelixis, Inc.\* | 10637 | 385272 |
| Geron Corp.\* | 284868 | 327598 |
| Gilead Sciences, Inc. | 3966 | 445342 |
| Halozyme Therapeutics, Inc.\* | 8148 | 488636 |
| Harmony Biosciences Holdings, Inc.\*<sup>(2)</sup> | 13333 | 469055 |
| ImmunityBio, Inc.\*<sup>(2)</sup> | 139309 | 342700 |
| Immunocore Holdings PLC (United Kingdom)\*<sup>(1)</sup> | 12472 | 408707 |
| Incyte Corp.\* | 6420 | 480794 |
| Insmed, Inc.\* | 4587 | 492093 |
| Ionis Pharmaceuticals, Inc.\* | 12476 | 536219 |
| Iovance Biotherapeutics, Inc.\* | 192378 | 494411 |
| Kiniksa Pharmaceuticals International PLC\* | 16026 | 484947 |
| Krystal Biotech, Inc.\* | 3167 | 487306 |
| Legend Biotech Corp.\*<sup>(1)</sup> | 11722 | 457979 |
| Ligand Pharmaceuticals, Inc.\* | 3883 | 510925 |
| Madrigal Pharmaceuticals, Inc.\* | 1495 | 452252 |
| Mirum Pharmaceuticals, Inc.\* | 9066 | 468531 |
| Moderna, Inc.\* | 16248 | 480291 |
| Neurocrine Biosciences, Inc.\* | 3555 | 455858 |
| Novavax, Inc.\* | 62153 | 413317 |
| Omniab, Inc. - $12.50 Earnout\*<sup>(3)</sup> | 1295 | 0 |
| Omniab, Inc. - $15.00 Earnout\*<sup>(3)</sup> | 1295 | 0 |
| Phathom Pharmaceuticals, Inc.\*<sup>(2)</sup> | 44306 | 378373 |
| PTC Therapeutics, Inc.\* | 8717 | 454243 |
| Regeneron Pharmaceuticals, Inc. | 852 | 464732 |
| Rhythm Pharmaceuticals, Inc.\* | 7052 | 601042 |
| Roivant Sciences Ltd.\* | 38744 | 440132 |
| Sarepta Therapeutics, Inc.\* | 11911 | 195579 |
| Tarsus Pharmaceuticals, Inc.\* | 10852 | 421275 |
| TG Therapeutics, Inc.\*<sup>(2)</sup> | 11892 | 422166 |
| Theravance Biopharma, Inc.\* | 41884 | 467425 |
| Travere Therapeutics, Inc.\* | 29745 | 459560 |
| Ultragenyx Pharmaceutical, Inc.\* | 11311 | 309017 |
| United Therapeutics Corp.\* | 1553 | 426609 |
| Vertex Pharmaceuticals, Inc.\* | 966 | 441336 |
| Zai Lab Ltd. (China)\*<sup>(1)(2)</sup> | 10328 | 390398 |
| Total Health Care |  | 24362819 |
| **Total Common Stocks** |  |  |
| (Cost $21,714,650) |  | **24362819** |

---

---

| | | |
|:---|:---|:---|
| **Security Description** | **Shares** | **Value** |
| **SECURITIES LENDING COLLATERAL - 1.6%** | **SECURITIES LENDING COLLATERAL - 1.6%** | **SECURITIES LENDING COLLATERAL - 1.6%** |
| **Money Market Fund - 1.6%** |  |  |
| Dreyfus Government Cash Management Fund, Institutional Shares, 4.20%<sup>(4)(5)</sup> |  |  |
| (Cost $400,769) | 400769 | $**400769** |
| **TOTAL INVESTMENTS - 100.5%** |  |  |
| (Cost $22,115,419) |  | **24763588** |
| Liabilities in Excess of Other Assets - (0.5)% |  | (118213) |
| **Net Assets - 100.0%** |  | $**24645375** |

---

\* Non-income producing security.

(1) American Depositary Receipts.

(2) All or a portion of the security was on loan. The aggregate market value of securities on loan was $1,540,902; total market value of collateral held by the Fund was $1,620,597. Market value of the collateral held includes non-cash U.S. Treasury securities having a value of $1,219,828.

(3) Security valued at fair value as determined in good faith by or under the direction of the Trustees. This security is disclosed as a Level 2 security in the Fair Value Hierarchy table located after the Schedule of Investments.

(4) Represents securities purchased with cash collateral received for securities on loan.

(5) The rate shown reflects the seven-day yield as of July 31, 2025.

Schedule of Investments - Virtus LifeSci Biotech Products ETF (continued)

July 31, 2025 (unaudited)

**Fair Value Measurements**

The Fund utilizes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 includes unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access. Level 2 includes observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data. Level 3 includes unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available; representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following table summarizes valuation of the Fund's investments under the fair value hierarchy levels as of July 31, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Asset Valuation Inputs** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stocks | $24362819 | $0 \* | $— | $24362819 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money Market Fund | 400769 |  |  | 400769 |
| **Total** | $**24763588** | $**0** | $**—** | $**24763588** |

---

\* Includes internally fair valued securities currently priced at zero ($0).

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** ETFis Series Trust I

- **b. Investment Company Act file number:** 811-22819

- **c. CIK number of Registrant:** 0001559109

- **d. LEI of Registrant:** 5493002CWTVLBPSYFT98

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 31 West 52nd Street

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10019

  - **Telephone number:** 347-903-7347

**Item A.2. Information about the Series.**

- **a. Name of Series:** Virtus LifeSci Biotech Products ETF

- **b. EDGAR series identifier (if any):** S000047354

- **c. LEI of Series:** 549300U4V8YBNY7O1032

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2025-10-31

- **b. Date as of which information is reported:** 2025-07-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $25062334.62

**Total Liabilities:** $416935.73

**Net Assets:** $24645398.89

**Cash Not Reported:** $295134.26

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000148682 | -4.91%               | 4.10%                | 5.47%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $0.00                    | $-1150202.53                               |
| Month 2  | $-1214403.35             | $2142447.30                                |
| Month 3  | $0.00                    | $1291746.28                                |

### Schedule of Portfolio Investments

| Name                           | Title                                     | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Tarsus Pharmaceuticals Inc     | Tarsus Pharmaceuticals Inc                | CUSIP: 87650L103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     10852 | NS      | $421274.64    | 1.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Iovance Biotherapeutics Inc    | Iovance Biotherapeutics Inc               | CUSIP: 462260100<br>LEI: 2549002L8WT2ACU5Q878 | Long             | EC               | CORP              | US        |    192378 | NS      | $494411.46    | 2.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Zai Lab Ltd                    | Zai Lab Ltd                               | CUSIP: 98887Q104<br>LEI: 549300P2UYQ9U5LY1T58 | Long             | EC               | CORP              | CN        |     10328 | NS      | $390398.40    | 1.58%             |  |  |  | No            |                  1 | On Loan: —       |
| THERAVANCE BIOPHARMA INC       | THERAVANCE BIOPHARMA INC                  | CUSIP: 000000000<br>LEI: 5493007VTSXP4Z6MIW52 | Long             | EC               | CORP              | KY        |     41884 | NS      | $467425.44    | 1.90%             |  |  |  | No            |                  1 | On Loan: No      |
| INCYTE CORP                    | INCYTE CORP                               | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |      6420 | NS      | $480793.80    | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Legend Biotech Corp            | Legend Biotech Corp                       | CUSIP: 52490G102<br>LEI: 254900EIUFZTW136H859 | Long             | EC               | CORP              | US        |     11722 | NS      | $457978.54    | 1.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Roivant Sciences Ltd           | Roivant Sciences Ltd                      | CUSIP: 000000000<br>LEI: 549300DL466NY5J6U724 | Long             | EC               | CORP              | US        |     38744 | NS      | $440131.84    | 1.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S            | Ascendis Pharma A/S                       | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |      2600 | NS      | $451100.00    | 1.83%             |  |  |  | No            |                  1 | On Loan: No      |
| ImmunityBio Inc                | ImmunityBio Inc                           | CUSIP: 45256X103<br>LEI: 529900J9XLBR4HFL4B83 | Long             | EC               | CORP              | US        |    139309 | NS      | $342700.14    | 1.39%             |  |  |  | No            |                  1 | On Loan: —       |
| Ardelyx Inc                    | Ardelyx Inc                               | CUSIP: 039697107<br>LEI: 549300F542QR4SXHCY32 | Long             | EC               | CORP              | US        |    119461 | NS      | $506514.64    | 2.06%             |  |  |  | No            |                  1 | On Loan: No      |
| BeOne Medicines Ltd            | BeOne Medicines Ltd                       | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | US        |      1607 | NS      | $483915.91    | 1.96%             |  |  |  | No            |                  1 | On Loan: No      |
| SAREPTA THERAPEUTICS INC       | SAREPTA THERAPEUTICS INC                  | CUSIP: 803607100<br>LEI: 549300IKDPIED8J8IG21 | Long             | EC               | CORP              | US        |     11911 | NS      | $195578.62    | 0.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals Inc     | Rhythm Pharmaceuticals Inc                | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |      7052 | NS      | $601041.96    | 2.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunocore Holdings PLC        | Immunocore Holdings PLC                   | CUSIP: 45258D105<br>LEI: 213800IUE3DFS84BVN18 | Long             | EC               | CORP              | GB        |     12472 | NS      | $408707.44    | 1.66%             |  |  |  | No            |                  1 | On Loan: No      |
| ULTRAGENYX PHARMACEUTICAL IN   | ULTRAGENYX PHARMACEUTICAL INC             | CUSIP: 90400D108<br>LEI: 529900EV44GVDN1DCX77 | Long             | EC               | CORP              | US        |     11311 | NS      | $309016.52    | 1.25%             |  |  |  | No            |                  1 | On Loan: No      |
| BIOGEN INC                     | BIOGEN INC                                | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |      3359 | NS      | $429952.00    | 1.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                     | Insmed Inc                                | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |      4587 | NS      | $492093.36    | 2.00%             |  |  |  | No            |                  1 | On Loan: No      |
| AGIOS PHARMACEUTICALS INC      | AGIOS PHARMACEUTICALS INC                 | CUSIP: 00847X104<br>LEI: 529900ONJHY8EOGYT555 | Long             | EC               | CORP              | US        |     12881 | NS      | $479430.82    | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| PTC Therapeutics Inc           | PTC Therapeutics Inc                      | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |      8717 | NS      | $454242.87    | 1.84%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics Inc        | Axsome Therapeutics Inc                   | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |      4183 | NS      | $424072.54    | 1.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc           | Bridgebio Pharma Inc                      | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |     11208 | NS      | $529802.16    | 2.15%             |  |  |  | No            |                  1 | On Loan: No      |
| TG Therapeutics Inc            | TG Therapeutics Inc                       | CUSIP: 88322Q108<br>LEI: 529900X21UKABN9NJ529 | Long             | EC               | CORP              | US        |     11892 | NS      | $422166.00    | 1.71%             |  |  |  | No            |                  1 | On Loan: —       |
| Novavax Inc                    | Novavax Inc                               | CUSIP: 670002401<br>LEI: 529900J4GJHPEPQ23205 | Long             | EC               | CORP              | US        |     62153 | NS      | $413317.45    | 1.68%             |  |  |  | No            |                  1 | On Loan: No      |
| OmniAb, Inc.                   | OmniAb, Inc.                              | CUSIP: 68218J301<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1295 | NS      | $0.00         | 0.00%             |  |  |  | No            |                  2 | On Loan: No      |
| Dynavax Technologies Corp      | Dynavax Technologies Corp                 | CUSIP: 268158201<br>LEI: 549300T5URIXWDILX594 | Long             | EC               | CORP              | US        |     42730 | NS      | $469175.40    | 1.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc    | Alnylam Pharmaceuticals Inc               | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |      1459 | NS      | $572278.16    | 2.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Travere Therapeutics Inc       | Travere Therapeutics Inc                  | CUSIP: 89422G107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     29745 | NS      | $459560.25    | 1.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Kiniksa Pharmaceuticals Intern | Kiniksa Pharmaceuticals International Plc | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     16026 | NS      | $484946.76    | 1.97%             |  |  |  | No            |                  1 | On Loan: No      |
| VERTEX PHARMACEUTICALS INC     | VERTEX PHARMACEUTICALS INC                | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |       966 | NS      | $441336.42    | 1.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Moderna Inc                    | Moderna Inc                               | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |     16248 | NS      | $480290.88    | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Amicus Therapeutics Inc        | Amicus Therapeutics Inc                   | CUSIP: 03152W109<br>LEI: 549300MRD1SMUTNBPQ53 | Long             | EC               | CORP              | US        |     72025 | NS      | $431429.75    | 1.75%             |  |  |  | No            |                  1 | On Loan: No      |
| HALOZYME THERAPEUTICS INC      | HALOZYME THERAPEUTICS INC                 | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |      8148 | NS      | $488635.56    | 1.98%             |  |  |  | No            |                  1 | On Loan: No      |
| DREYFUS GOVERNMENT CASH MANAGE | DREYFUS GOVERNMENT CASH MANAGE            | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | RF                | US        |    400769 | NS      | $400769.20    | 1.63%             |  |  |  | No            |                  1 | On Loan: No      |
| IONIS PHARMACEUTICALS INC      | IONIS PHARMACEUTICALS INC                 | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |     12476 | NS      | $536218.48    | 2.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Apellis Pharmaceuticals Inc    | Apellis Pharmaceuticals Inc               | CUSIP: 03753U106<br>LEI: 254900HS0ZFRXXSB9D42 | Long             | EC               | CORP              | US        |     23073 | NS      | $515450.82    | 2.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                      | Amgen Inc                                 | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |      1495 | NS      | $441174.50    | 1.79%             |  |  |  | No            |                  1 | On Loan: No      |
| REGENERON PHARMACEUTICALS      | REGENERON PHARMACEUTICALS INC             | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |       852 | NS      | $464731.92    | 1.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Day One Biopharmaceuticals Inc | Day One Biopharmaceuticals Inc            | CUSIP: 23954D109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     66427 | NS      | $445725.17    | 1.81%             |  |  |  | No            |                  1 | On Loan: No      |
| Madrigal Pharmaceuticals Inc   | Madrigal Pharmaceuticals Inc              | CUSIP: 558868105<br>LEI: 549300CHIMT2EUSNJB60 | Long             | EC               | CORP              | US        |      1495 | NS      | $452252.45    | 1.84%             |  |  |  | No            |                  1 | On Loan: No      |
| EXELIXIS INC                   | EXELIXIS INC                              | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |     10637 | NS      | $385272.14    | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Geron Corp                     | Geron Corp                                | CUSIP: 374163103<br>LEI: 549300T282D7Z2YESL90 | Long             | EC               | CORP              | US        |    284868 | NS      | $327598.20    | 1.33%             |  |  |  | No            |                  1 | On Loan: No      |
| UNITED THERAPEUTICS CORP       | UNITED THERAPEUTICS CORP                  | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |      1553 | NS      | $426609.10    | 1.73%             |  |  |  | No            |                  1 | On Loan: No      |
| LIGAND PHARMACEUTICALS         | LIGAND PHARMACEUTICALS INC                | CUSIP: 53220K504<br>LEI: 5493008K7TB0IKP37H79 | Long             | EC               | CORP              | US        |      3883 | NS      | $510925.14    | 2.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Mirum Pharmaceuticals Inc      | Mirum Pharmaceuticals Inc                 | CUSIP: 604749101<br>LEI: 254900YZKR40F7F27K81 | Long             | EC               | CORP              | US        |      9066 | NS      | $468530.88    | 1.90%             |  |  |  | No            |                  1 | On Loan: No      |
| ADMA Biologics Inc             | ADMA Biologics Inc                        | CUSIP: 000899104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     20574 | NS      | $384733.80    | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| OmniAb, Inc.                   | OmniAb, Inc.                              | CUSIP: 68218J202<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1295 | NS      | $0.00         | 0.00%             |  |  |  | No            |                  2 | On Loan: No      |
| Harmony Biosciences Holdings I | Harmony Biosciences Holdings Inc          | CUSIP: 413197104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     13333 | NS      | $469054.94    | 1.90%             |  |  |  | No            |                  1 | On Loan: —       |
| CRISPR Therapeutics AG         | CRISPR Therapeutics AG                    | CUSIP: 000000000<br>LEI: 506700O6IRRIQLT3W370 | Long             | EC               | CORP              | CH        |     10765 | NS      | $605638.90    | 2.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Phathom Pharmaceuticals Inc    | Phathom Pharmaceuticals Inc               | CUSIP: 71722W107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     44306 | NS      | $378373.24    | 1.54%             |  |  |  | No            |                  1 | On Loan: —       |
| Aurinia Pharmaceuticals Inc    | Aurinia Pharmaceuticals Inc               | CUSIP: 05156V102<br>LEI: 5299008YP2BW4570ML28 | Long             | EC               | CORP              | CA        |     53997 | NS      | $499202.27    | 2.03%             |  |  |  | No            |                  1 | On Loan: No      |
| BioCryst Pharmaceuticals Inc   | BioCryst Pharmaceuticals Inc              | CUSIP: 09058V103<br>LEI: 549300Z0INP1Z5NP6J59 | Long             | EC               | CORP              | US        |     42730 | NS      | $347822.20    | 1.41%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                    | BioNTech SE                               | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |      4236 | NS      | $455370.00    | 1.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Krystal Biotech Inc            | Krystal Biotech Inc                       | CUSIP: 501147102<br>LEI: 549300YONUY68210OE41 | Long             | EC               | CORP              | US        |      3167 | NS      | $487306.29    | 1.98%             |  |  |  | No            |                  1 | On Loan: No      |
| NEUROCRINE BIOSCIENCES INC     | NEUROCRINE BIOSCIENCES INC                | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |      3555 | NS      | $455857.65    | 1.85%             |  |  |  | No            |                  1 | On Loan: No      |
| GILEAD SCIENCES INC            | GILEAD SCIENCES INC                       | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |      3966 | NS      | $445342.14    | 1.81%             |  |  |  | No            |                  1 | On Loan: No      |
| ACADIA Pharmaceuticals Inc     | ACADIA Pharmaceuticals Inc                | CUSIP: 004225108<br>LEI: 529900O3044NO0PEA039 | Long             | EC               | CORP              | US        |     20441 | NS      | $487109.03    | 1.98%             |  |  |  | No            |                  1 | On Loan: No      |
| BIOMARIN PHARMACEUTICAL INC    | BIOMARIN PHARMACEUTICAL INC               | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |      7758 | NS      | $448800.30    | 1.82%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-09-29

**Name of Applicant:** ETFis Series Trust I

**Signature:** Brinton W. Frith

**Name of Signer:** Brinton W. Frith

**Title:** Treasurer and Principal Financial Officer